#ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u available, but hard to interpret Remember this is a different population (non radiographic) than the upadacitinib trial that was also presented @RheumNow https://t.co/tkYEfiqj7h